GLPBio

Signaling Pathways

Research Area, Signaling Pathways | GlpBio Life Science Products Suppliers

Read More about this category

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs. At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development.

ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells. Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs. Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug. First generation ADCs made use of early cytotoxins such as the anthracycline, doxorubicin or the anti-metabolite/antifolate agent, methotrexate. Current cytotoxins have far greater potency and can be divided into three main groups: auristatins, maytansines and calicheamicins.

The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.

References:

[1] Tsuchikama K, et al. Protein Cell. 2016 Oct 14. DOI:10.1007/s13238-016-0323-0.

[2] Peters C, et al. Biosci Rep. 2015 Jun 12;35(4). pii: e00225. doi: 10.1042/BSR20150089.

Research Areas

Products Related to Signaling Pathways(40823)

  • GC79808 structure
    GC79808SAR113945 monopotassium
    CAS: 899418-65-6
    Purity: >98.00%

    SAR113945 monopotassium is a highly selective IKK-β inhibitor with an IC 50 value of 0.4 nM.

  • GC79809 structure
    GC79809TBK1 ligand 3
    CAS: 2115897-10-2
    Purity: >99.00%

    TBK1 ligand 3 is a TBK1 ligand, which can be used as a target protein ligand for the synthesis of PROTAC UNC8209 and UNC8461 [1] .

  • GC79810 structure
    GC79810MLN-0415
    CAS: 1147862-78-9
    Purity: >98.00%

    MLN-0415 is an IKKβ inhibitor.

  • GC79811 structure
    GC79811Tat-IKIP (46-60) TFA
    Purity: >99.50%

    Tat-IKIP (46-60) TFA is the trifluoroacetic acid of Tat-IKIP (46-60).

  • GC79812 structure
    GC79812CDDO-biotin
    CAS: 3110422-01-7
    Purity: >96.50%

    CDDO-biotin is an IKKβ inhibitor with cancer cell inhibitory activity.

  • GC79813 structure
    GC79813Arvelexin
    CAS: 4837-74-5
    Purity: >98.00%

    Arvelexin is a biologically active compound.

  • GC79814 structure
    GC79814Isosorbide di-(methyl fumarate)
    CAS: 2013542-44-2
    Purity: >99.50%

    Isosorbide di-(methyl fumarate) (IDMF), topical DMF derivative, is an NRF2/ARE pathway activator.

  • GC79815 structure
    GC79815(E/Z)-Sinigrin free base
    CAS: 534-69-0
    Purity: >98.00%

    (E/Z)-Sinigrin ((E/Z)-Allyl-glucosinolate; (E/Z)-2-Propenyl-glucosinolate) free base is an orally active aliphatic thioglucoside anti-leukemia compound.

  • GC79816 structure
    GC79816Cryptolepine
    CAS: 480-26-2
    Purity: >98.00%

    Cryptolepine is an orally active multi-potent alkaloid with anti-cancer, anti-bacterial, anti-viral, anti-malarial, anti-inflammatory, anti-hyperglycemic, relieve pain and other properties.

  • GC79817 structure
    GC79817DL-Propargylglycine sodium
    CAS: 73823-66-2
    Purity: >95.00%

    DL-Propargylglycine sodium is a Glycine derivative.

  • GC79818 structure
    GC79818Oxindolylalanine
    CAS: 32999-55-6
    Purity: >98.00%

    Oxindolylalanine, a tryptophan analogue, is an inhibitor of tryptophan indole-lyase (K i: 5 μM) and tryptophan synthase.

  • GC79819 structure
    GC79819Cyclo(leucylleucine)
    CAS: 952-45-4
    Purity: >98.50%

    Cyclo(leucylleucine) is a cyclic dipeptide formed by the cyclization of two leucine molecules via peptide bonds, and it can be used in the preparation of nanomaterials [1] .

  • GC79820 structure
    GC798202-Amino-4-(2-aminoethoxy)butanoic acid dihydrochloride
    Purity: >98.50%

    2-Amino-4-(2-aminoethoxy)butanoic acid dihydrochloride is an amino acid derivative that can be isolated from Streptomyces [1] .

  • GC79821 structure
    GC79821H-Glu-Pro-OH
    CAS: 41745-47-5
    Purity: >98.00%

    H-Glu-Pro-OH is a Xaa-Pro dipeptide with affinity for the intestinal H + /peptide cotransporter (PEPT1), with a K i value of 0.26 mM [1] .

  • GC79822 structure
    GC79822Tet-v2.0-ethyl hydrochloride
    Purity: >98.00%

    Tet-v2.0-ethyl hydrochloride is a tetrazine non-canonical amino acid.

  • GC79823 structure
    GC79823H-Met-Pro-OH acetate
    Purity: >98.00%

    H-Met-Pro-OH acetate is a dipeptide containing methionine and proline.

  • GC79824 structure
    GC79824H-His-Arg-OH
    CAS: 77369-21-2
    Purity: >98.00%

    H-His-Arg-OH is a dipeptide containing guanidine groups.

  • GC79825 structure
    GC79825Mal-L-Dap(Boc, t-BuOAc)-OH
    CAS: 2750622-89-8
    Purity: >99.50%

    Mal-L-Dap(Boc, t-BuOAc)-OH is an L-Dap (non-protein amino acid) derivative [1] .

  • GC79826 structure
    GC79826KRAS WT Peptide TFA
    Purity: >98.50%

    KRAS WT Peptide TFA is the trifluoroacetate salt of KRAS WT Peptide.

  • GC79827 structure
    GC79827E12LA6B6O3
    CAS: 3109642-25-0
    Purity: >98.00%

    E12LA6B6O3 is an amino lipid that can be used to prepare nanoparticles for drug delivery, such as mRNA [1] .

  • GC79828 structure
    GC79828OVA-A2 Peptide acetate
    Purity: >98.00%

    OVA-A2 Peptide (SAINFEKL, OVA (257-264) Variant) acetate is a biological active peptide.

  • GC79829 structure
    GC79829MH42 TFA
    Purity: >96.50%

    MH42 TFA, a peptide, shows high binding to RPE cells [1] .

  • GC79830 structure
    GC79830CTP-Cys
    CAS: 2300065-35-2
    Purity: >95.50%

    CTP -Cys is a cysteine attached to CTP for peptide conjugation [1] .

  • GC79831 structure
    GC79831TAT (47-57), TAMRA-labeled acetate
    Purity: >98.50%

    TAT (47-57), TAMRA-labeled acetate is a fluorescently labeled cell-penetrating peptide derived from the HIV-1 transactivator of transcription (TAT).